Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer.

Signal Transduct Target Ther · 2022 · PMC8813937 · PMID 35115484

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Additionally, the TCGA database analysis revealed a decreasing trend in cytl1 expression during breast cancer progression (Supplementary Fig.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.